

Achieved 100% of the Enrollment Goal in a Phase 4 Obesity and Plaque Psoriasis Trial

Our Objectives

DelRicht Research was selected as a participating site network for a Phase 4 trial targeting adults with obesity and psoriasis. The trial aimed to recruit adults ≥ 18 with a moderate-to-severe plaque psoriasis diagnosis and obesity or other weight-related comorbidity.

- **Study Enrollment Goal:** 200 patients across 40 sites
- **DelRicht's Enrollment Goal:** 5 patients across 1 site
- **Patient Population:** Adults ≥ 18 years old
- **Enrollment Period:** June 2025 – June 2026 (12 months)

Key Trial Challenges

- 1 **Eligibility Criteria:**
Strict eligibility criteria requiring **incretin-naïve status**, **drug lead-in windows**, and **BMI thresholds** narrowed the eligible pool.
- 2 **Visit Frequency:**
Long **6- and 12-month visit gaps** introduced opportunities for discontinuation and incomplete data capture.

Solutions Implemented

- 1 **Targeted Recruitment :**
We leveraged **established referral networks** & **patient word-of-mouth referrals** to identify qualifying psoriasis patients.
- 2 **Long-Term Engagement:**
The site maintained engagement during the lead-in and treatment period using **reminders** and **dedicated coordinators for follow-up**.

Our Results

DelRicht's site in Smyrna, TN successfully enrolled **5 patients** and **100% of the expected goal**. This success underscores DelRicht's commitment to high-quality execution, patient engagement, and partnership-driven results.



5 Participants Enrolled




100% of the Expected Enrollment Goal

The Study

Client: Large-Size Biopharma

Trial: U.S. Phase 4 Obesity & Moderate-to-Severe Psoriasis

Participating PIs



Dr. Pezhman Shoureshi
Smyrna, TN

Harpeth Valley Dermatology

